Pharmacological Approaches in Pain Management. Ryan J. Bickel, Pharm.D., BCPS updated by David G. Curry, PhD, APRN for NUR344, Fall, 2009 Used with permission. Learning Objectives. Review common non-opioid, opioid, and adjuvant analgesic medications
Related searches for
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Ryan J. Bickel, Pharm.D., BCPS
David G. Curry, PhD, APRN for
NUR344, Fall, 2009
Used with permission
Effective as APAP for acute pain at similar doses
Worse side effect profile than APAP
Safer than ASA
No platelet effects
Magnesium salicylate (Doan’s)Salicylates
constipation, physical dependence
Not a first line agent!
Note: Heat increases rate of release from patch
than APAP alone
causes withdrawal in patients on opioids
ceiling effect on analgesia
psychotomimetic adverse effects
Lower abuse potential
Pentazocine (Talwin, Talwin NX)
Buprenorphine (Buprenex)Mixed Agonist-Antagonists
“drugs that are used primarily for treating conditions other than pain, but may be analgesic in selected circumstances”
MJ is a 56 YOM with prostate cancer admitted to hospital for pain control. He was started on a morphine PCA. In the last 24 hours the patient has received 34 mg and his pain has been adequately control. The physician discontinued the PCA and started the patient on MSContin 30 mg PO BID. Is this an equivalent regimen?
Table IV dose
Table PO dose
Pt 24 hr IV dose
X amount of PO
10 mg IV
30 mg PO
30 mg PO
34 mg IV
34 mg IV
XEquianalgesic Case 1
Set up proportion
10X = 1020
Divide each side by the number in front of X:
Select Reasonable Regimen
MS Contin 45 mg PO BID
X = 102
Calculate the oral morphine dose needed for breakthrough pain
Answer: Morphine 5 – 15 mg PO every 4 hours prn pain
PJ is a 47 YO female who is receiving morphine 2-6 mg IV q2h prn post-op. In the last 24 hours, the patient has received 24 mg IV morphine. Surgery just dc’d the morphine & ordered Lortab 5/500 mg 1-2 tabs PO q6h PRN pain. What do you think of this regimen?
X = 72 mg PO morphineEquinalagesic Case 2
Convert to oral morphine:
10 mg IV
30 mg PO
24 mg IV
X = 48 mg hydrocodoneEquinalagesic Case 2
Convert to hydrocodone:
30 mg MS
20 mg HC
72 mg MS
1. Pain Management Part 1: Overview of Physiology, Assessment, and Treatment. Chicago, IL, American Medical Association, 2003.
2. Li JM. Pain management in the hospitalized patient. Med Clin N Am 2002; 86: 771-95.
3. Sachs CJ. Oral analgesics for acute nonspecific pain. Am Fam Physician 2005; 71: 913-18.
4. Frampton JE, Keating GM. Celecoxib: A review of its use in the management of arthritis and acute pain. Drugs 2007; 67: 2433-72.
5. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11: S133-53.
6. Emanuel LL, von Gunten CF, Ferris FD, eds. The Education for Physicians on End-of-life Care (EPEC) Curriculum. EPEC Project, The Robert Wood Johnson Foundation, 1999, Module 4.
7. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18 : S3-S13.
8. Lexi-Drugs (Comp + Specialty) [computer program]. Lexi-Comp. October 24, 2008.
9. Nickel EJ, Smith T. Analgesia in the intensive care unit: pharmacologic and pharmacokinetic considerations.Crit Care Nurs Clin North America 2001; 13: 207-17.
10. Gardner-Nix J. Principles of opioid use in chronic noncancer pain. Can Med Assoc J 2003; 169:
11. Baker DE. Meperidine: a drug past its prime. Hosp Pharmacy 2001; 36: 1131-32.
12. Auret K, Schug SA. Underutilization of opioids in elderly patients with chronic pain. Drugs Aging 2005; 22: 641-54.
13. Walsh D. Pharmacological management of cancer pain. Semin Oncol 2000; 27: 45-63.
14. Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician 2005; 71: 1353-8.
15. Rapp CJ, Gordon DB. Understanding equianalgesic dosing. Orthop Nurs 2000; 19: 65-72.
16. Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997; 24: S16-13 – S16-19.